Rosiglitazone ameliorates acute hepatic injury via activating the Nrf2 signaling pathway and inhibiting activation of the NLRP3 inflammasome

Ma,Ling; Ma,Ying; Ma,Bin-Xi; Ma,Ming

doi:10.3892/etm.2022.11229

Rosiglitazone ameliorates acute hepatic injury via activating the Nrf2 signaling pathway and inhibiting activation of the NLRP3 inflammasome

Authors:
- Ling Ma
- Ying Ma
- Bin-Xi Ma
- Ming Ma
View Affiliations

Affiliations: Department of Pharmacy, The Eighth Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830049, P.R. China, Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China, Department of Hepatobiliary Surgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang 830000, P.R. China
Published online on: February 21, 2022 https://doi.org/10.3892/etm.2022.11229
Article Number: 300
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute hepatic injury is a common liver disease in clinical practice. Drugs with antioxidant activity exhibit a great potential for alleviating liver injury. The present study aimed to explore the role of rosiglitazone (RSG), a previously reported compound with anti‑inflammatory properties, in hepatic injury. Kunming mice were divided into the following four groups: The control group; the RSG group; the carbon tetrachloride (CCl₄) group; and the RSG + CCl₄ group. Hepatic injury was confirmed by histological examination of the liver. In addition, the serum levels of alanine transaminase (ALT) and aspartate transaminase (AST), and those of the biochemical indices superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), malondialdehyde (MDA), NO and reactive oxygen species (ROS) were measured in each group of mice. Additionally, the levels of inflammatory factors and apoptosis‑related proteins, as well as the activity of the related signaling pathways, were evaluated. The results showed that RSG could reverse the CCl4‑mediated decrease in the levels of SOD, CAT and GSH, and increase in the levels of ALT, AST, MDA, NO and ROS. Furthermore, treatment with RSG could reduce the expression levels of inflammation‑ and apoptosis‑related proteins, thus suggesting that RSG could attenuate inflammation and liver cell apoptosis. Additionally, treatment with RSG promoted the activation of the nuclear factor erythroid 2‑related factor 2 (Nrf2) signaling pathway, upregulated peroxisome proliferator‑activated receptor γ and inhibited activation of the inflammasome NOD‑like receptor protein 3 (NLRP3). In conclusion, the current study demonstrated that RSG could ameliorate acute hepatic injury via activating the Nrf2 signaling pathway and inhibiting activation of the NLRP3 inflammasome. The findings of the present study partly uncovered the mechanism underlying the effect of RSG on hepatic injury, thus supporting the application of RSG in clinical practice.

View Figures

View References

1	Coccolini F, Coimbra R, Ordonez C, Kluger Y, Vega F, Moore EE, Biffl W, Peitzman A, Horer T, Abu-Zidan FM, et al: Liver trauma: WSES 2020 guidelines. World J Emerg Surg. 15(24)2020.PubMed/NCBI View Article : Google Scholar
2	Zou Y, Xiong JB, Ma K, Wang AZ and Qian KJ: Rac2 deficiency attenuates CCl₄-induced liver injury through suppressing inflammation and oxidative stress. Biomed Pharmacother. 94:140–149. 2017.PubMed/NCBI View Article : Google Scholar
3	Zhang X, Kuang G, Wan J, Jiang R, Ma L, Gong X and Liu X: Salidroside protects mice against CCl4-induced acute liver injury via down-regulating CYP2E1 expression and inhibiting NLRP3 inflammasome activation. Int Immunopharmacol. 85(106662)2020.PubMed/NCBI View Article : Google Scholar
4	Cichoż-Lach H and Michalak A: Oxidative stress as a crucial factor in liver diseases. World J Gastroenterol. 20:8082–8091. 2014.PubMed/NCBI View Article : Google Scholar
5	Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW and Feng Y: The role of oxidative stress and antioxidants in liver diseases. Int J Mol Sci. 16:26087–26124. 2015.PubMed/NCBI View Article : Google Scholar
6	Cong M, Zhao W, Liu T, Wang P, Fan X, Zhai Q, Bao X, Zhang D, You H, Kisseleva T, et al: Protective effect of human serum amyloid P on CCl4-induced acute liver injury in mice. Int J Mol Med. 40:454–464. 2017.PubMed/NCBI View Article : Google Scholar
7	Tsai TH, Tam K, Chen SF, Liou JY, Tsai YC, Lee YM, Huang TY and Shyue SK: Deletion of caveolin-1 attenuates LPS/GalN-induced acute liver injury in mice. J Cell Mol Med. 22:5573–5582. 2018.PubMed/NCBI View Article : Google Scholar
8	Stage TB, Christensen MH, Jørgensen NR, Beck-Nielsen H, Brøsen K, Gram J and Frost M: Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes. Bone. 112:35–41. 2018.PubMed/NCBI View Article : Google Scholar
9	Li J, Xue YM, Zhu B, Pan YH, Zhang Y, Wang C and Li Y: Rosiglitazone Elicits an Adiponectin-Mediated Insulin-Sensitizing Action at the Adipose Tissue-Liver Axis in Otsuka Long-Evans Tokushima Fatty Rats. J Diabetes Res. 2018(4627842)2018.PubMed/NCBI View Article : Google Scholar
10	Ahn KO, Lim SW, Yang HJ, Li C, Sugawara A, Ito S, Choi BS, Kim YS, Kim J and Yang CW: Induction of PPAR gamma mRNA and protein expression by rosiglitazone in chronic cyclosporine nephropathy in the rat. Yonsei Med J. 48:308–316. 2007.PubMed/NCBI View Article : Google Scholar
11	Yu X, Shao XG, Sun H, Li YN, Yang J, Deng YC and Huang YG: Activation of cerebral peroxisome proliferator-activated receptors gamma exerts neuroprotection by inhibiting oxidative stress following pilocarpine-induced status epilepticus. Brain Res. 1200:146–158. 2008.PubMed/NCBI View Article : Google Scholar
12	Gong P, Stewart D, Hu B, Li N, Cook J, Nel A and Alam J: Activation of the mouse heme oxygenase-1 gene by 15-deoxy-Delta(12,14)-prostaglandin J(2) is mediated by the stress response elements and transcription factor Nrf2. Antioxid Redox Signal. 4:249–257. 2002.PubMed/NCBI View Article : Google Scholar
13	Wang X, Wang Z, Liu JZ, Hu JX, Chen HL, Li WL and Hai CX: Double antioxidant activities of rosiglitazone against high glucose-induced oxidative stress in hepatocyte. Toxicol In Vitro. 25:839–847. 2011.PubMed/NCBI View Article : Google Scholar
14	Ravan AP, Bahmani M, Ghasemi Basir HR, Salehi I and Oshaghi EA: Hepatoprotective effects of Vaccinium arctostaphylos against CCl4-induced acute liver injury in rats. J Basic Clin Physiol Pharmacol. 28:463–471. 2017.PubMed/NCBI View Article : Google Scholar
15	National Research Council of the National Academies: Guide for the Care and Use of Laboratory Animals. 8th edition. The National Academies Press, Washington, DC, 2011.
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
17	Farzanegi P, Dana A, Ebrahimpoor Z, Asadi M and Azarbayjani MA: Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation. Eur J Sport Sci. 19:994–1003. 2019.PubMed/NCBI View Article : Google Scholar
18	Wei PC, Chang AN, Kao J, Du Z, Meyers RM, Alt FW and Schwer B: Long Neural Genes Harbor Recurrent DNA Break Clusters in Neural Stem/Progenitor Cells. Cell. 164:644–655. 2016.PubMed/NCBI View Article : Google Scholar
19	Melchart D, Hager S, Albrecht S, Dai J, Weidenhammer W and Teschke R: Herbal Traditional Chinese Medicine and suspected liver injury: A prospective study. World J Hepatol. 9:1141–1157. 2017.PubMed/NCBI View Article : Google Scholar
20	Dormandy TL: Free-radical pathology and medicine. A review. J R Coll Physicians Lond. 23:221–227. 1989.PubMed/NCBI
21	Popović B, Velimirović M, Stojković T, Brajović G, De Luka SR, Milovanović I, Stefanović S, Nikolić D, Ristić-Djurović JL, Petronijević ND and Trbovich AM: The influence of ageing on the extrapineal melatonin synthetic pathway. Exp Gerontol. 110:151–157. 2018.PubMed/NCBI View Article : Google Scholar
22	D'Agostino J, Zhang H, Kenaan C and Hollenberg PF: Mechanism-based inactivation of human cytochrome P450 2B6 by chlorpyrifos. Chem Res Toxicol. 28:1484–1495. 2015.PubMed/NCBI View Article : Google Scholar
23	Cui X, Gong J, Han H, He L, Teng Y, Tetley T, Sinharay R, Chung KF, Islam T, Gilliland F, et al: Relationship between free and total malondialdehyde, a well-established marker of oxidative stress, in various types of human biospecimens. J Thorac Dis. 10:3088–3097. 2018.PubMed/NCBI View Article : Google Scholar
24	Ohara M, Ohnishi S, Hosono H, Yamamoto K, Yuyama K, Nakamura H, Fu Q, Maehara O, Suda G and Sakamoto N: Extracellular vesicles from amnion-derived mesenchymal stem cells ameliorate hepatic inflammation and fibrosis in rats. Stem Cells Int. 2018(3212643)2018.PubMed/NCBI View Article : Google Scholar
25	Chen MF, Huang SJ, Huang CC, Liu PS, Lin KI, Liu CW, Hsieh WC, Shiu LY and Chen CH: Saikosaponin d induces cell death through caspase-3-dependent, caspase-3-independent and mitochondrial pathways in mammalian hepatic stellate cells. BMC Cancer. 16(532)2016.PubMed/NCBI View Article : Google Scholar
26	Mansouri A, Gattolliat CH and Asselah T: Mitochondrial dysfunction and signaling in chronic liver diseases. Gastroenterology. 155:629–647. 2018.PubMed/NCBI View Article : Google Scholar
27	Okoye CN, MacDonald-Jay N and Kamunde C: Effects of bioenergetics, temperature and cadmium on liver mitochondria reactive oxygen species production and consumption. Aquat Toxicol. 214(105264)2019.PubMed/NCBI View Article : Google Scholar
28	Zhu R, Wang Y, Zhang L and Guo Q: Oxidative stress and liver disease. Hepatol Res. 42:741–749. 2012.PubMed/NCBI View Article : Google Scholar
29	No JH, Kim YB and Song YS: Targeting nrf2 signaling to combat chemoresistance. J Cancer Prev. 19:111–117. 2014.PubMed/NCBI View Article : Google Scholar
30	Bataille AM and Manautou JE: Nrf2: A potential target for new therapeutics in liver disease. Clin Pharmacol Ther. 92:340–348. 2012.PubMed/NCBI View Article : Google Scholar
31	Dodson M, de la Vega MR, Cholanians AB, Schmidlin CJ, Chapman E and Zhang DD: Modulating NRF2 in disease: Timing is everything. Annu Rev Pharmacol Toxicol. 59:555–575. 2019.PubMed/NCBI View Article : Google Scholar
32	Shin SM, Yang JH and Ki SH: Role of the Nrf2-ARE pathway in liver diseases. Oxid Med Cell Longev. 2013(763257)2013.PubMed/NCBI View Article : Google Scholar
33	Chan K, Han XD and Kan YW: An important function of Nrf2 in combating oxidative stress: Detoxification of acetaminophen. Proc Natl Acad Sci USA. 98:4611–4616. 2001.PubMed/NCBI View Article : Google Scholar
34	Xu Y, Tang Y, Lu J and Zhang W, Zhu Y, Zhang S, Ma G, Jiang P and Zhang W: PINK1-mediated mitophagy protects against hepatic ischemia/reperfusion injury by restraining NLRP3 inflammasome activation. Free Radic Biol Med. 160:871–886. 2020.PubMed/NCBI View Article : Google Scholar
35	Wree A, McGeough MD, Inzaugarat ME, Eguchi A, Schuster S, Johnson CD, Peña CA, Geisler LJ, Papouchado BG, Hoffman HM and Feldstein AE: NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL-17 and TNF in mice. Hepatology. 67:736–749. 2018.PubMed/NCBI View Article : Google Scholar
36	Strowig T, Henao-Mejia J, Elinav E and Flavell R: Inflammasomes in health and disease. Nature. 481:278–286. 2012.PubMed/NCBI View Article : Google Scholar